AMGEN Inc
NASDAQ: AMGN
$280.01
-$13.99 (-4.8%)
Closing Price on November 26, 2024
AMGN Articles
Here are some of the top biotech names to buy at Cowen. They presented such an extensive list that we focused on the quality large cap names and the stocks with the highest upside to their target...
Published:
The Cowen biotechnology team has a list of top 10 surprises that are specific to the very hot biotechnology sector.
Published:
ThinkstockInvestors love dividends, particularly safe and dependable dividends that rise through time. The S&P 500 Index currently has the most companies paying dividends in nearly two decades....
Published:
ThinkstockThe market for pharmaceuticals and biotech drugs just keeps growing. The so-called patent cliff may be affecting Big Pharma companies locally, but a new report from IMS Health shows that...
Published:
ThinkstockMany Wall Street analysts and strategists are forecasting a rise in corporate earnings for the rest of the year and throughout 2014. That is music to the ears of stock investors. Rising...
Published:
Last Updated:
ThinkstockThe UBS proprietary institutional flow data indicates that hedge funds are increasing exposure to financials and decreasing exposure to health care. Given that health care has outperformed...
Published:
Last Updated:
Jon OggThe S&P 500 Index is hitting all-time highs and we are now deep into earnings season. This week will mark the second week of the earnings floodgates being open. 24/7 Wall St. has decided...
Published:
ThinkstockThe world of biotechnology investing is a constantly evolving and changing one. While disease for the most part does not change all that much, the manner in which it can be treated does....
Published:
Last Updated:
ThinkstockThe field of pharmaceuticals is very well established and often is considered to be a very defensive sector. As such, investors flock to the drug sector in times of uncertainty. But what...
Published:
ThinkstockTuesday saw the wrap up of the 2013 European Society of Medical Oncology (ESMO) conference in Amsterdam, which featured key data from several of the companies covered by the biotech...
Published:
Last Updated:
ThinkstockEven though the equity strategy team at UBS has downgraded U.S. equities to Neutral from Outperform, they remain very positive on large cap biotechnology names. Acknowledging in their...
Published:
Last Updated:
Jon OggAny time you see a merger announcement, you see a myriad of press releases pertaining to law firms and lawyers investigating the terms of the deal. This is in one sense the new form of class...
Published:
Jon OggThis will be an interesting week for Wall Street analyst coverage as many traders, investors and analysts are out ahead of Labor Day. Still, we are seeing a surprising number of research calls...
Published:
ThinkstockAmgen Inc. (NASDAQ: AMGN) wants to regain its status as the largest publicly traded biotech in the U.S. The company formalized a buyout of cancer drug maker Onyx Pharmaceuticals Inc....
Published:
ThinkstockWith the Federal Reserve reminding investors yesterday that it can raise or lower asset purchases in its quantitative easing program based on the data, all eyes shift to tomorrow’s...
Published:
Last Updated: